ClinicalTrials.gov
ClinicalTrials.gov Menu

Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01379352
Recruitment Status : Completed
First Posted : June 23, 2011
Last Update Posted : December 25, 2013
Sponsor:
Information provided by (Responsible Party):
Gaab Soo Kim, Samsung Medical Center

Brief Summary:
The vecuronium requirements may be reduced for recipients of living donor liver transplantation, as the vecuronium is eliminated principally by the liver. Furthermore, the requirements may be different according to the phase of surgery. The requirements may also be different according to the preoperative hepatic function as measured by MELD score during prehepatic phase, or graft to recipient body weight ratio (GRWR) during neohepatic phase. Therefore, the investigators are trying to investigate the difference of vecuronium requirements according to the phase of surgery or MELD score, GRWR.

Condition or disease
Liver Transplantation

Detailed Description:

The vecuronium requirements may be reduced for recipients of living donor liver transplantation, as the vecuronium is eliminated principally by the liver. Furthermore, the requirements may be different according to the phase of surgery. The requirements may by further reduced during anhepatic phase of liver transplantation. And the requirements may be increased as the graft functions during neohepatic phase.

We also postulated that the requirements may be different according to the preoperative hepatic function during preanhepatic phase, and according to the graft to recipient body weight ratio (GRWR) during neohepatic phase.

Therefore, we are trying to investigate the difference of vecuronium requirements according to the phase of surgery, MELD score, GRWR.


Study Type : Observational
Actual Enrollment : 35 participants
Time Perspective: Prospective
Official Title: Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia
Study Start Date : June 2011
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine


Group/Cohort
High MELD group
Preoperative MELD score greater than 20
Low MELD group
Preoperative MELD score lesser than 20



Primary Outcome Measures :
  1. vecuronium requirements during preanhepatic phase [ Time Frame: during prehepatic phase of liver transplantation ]
    total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during preanhepatic phase

  2. vecuronium requirements during anhepatic phase [ Time Frame: during anhepatic phase of liver transplantation ]
    total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during anhepatic phase

  3. vecuronium requirements during neohepatic phase [ Time Frame: during neohepatic phase of liver transplantation ]
    total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during neohepatic phase



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing elective living donor liver transplantation
Criteria

Inclusion Criteria:

  • patients undergoing elective living donor liver transplantation

Exclusion Criteria:

  • patients who can not undergo train-of-four test due to central or peripheral neuromuscular disease.
  • patients with severe cardiopulmonary diseases.
  • patients who received transfusion with more than 10 units of packed red blood cells.
  • primary non-functioning graft immediately after reperfusion of the graft.
  • patients who administered drugs that influences the metabolism of vecuronium (such as anticonvulsant: phenytoin, carbamazepine, primidone, sodium valproate)
  • patients undergoing cadaver donor liver transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01379352


Locations
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
Samsung Medical Center
Investigators
Study Director: Gaab Soo Kim, M.D.,Ph.D. Samsung Medical Center

Responsible Party: Gaab Soo Kim, Professor, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT01379352     History of Changes
Other Study ID Numbers: 2011-04-015
First Posted: June 23, 2011    Key Record Dates
Last Update Posted: December 25, 2013
Last Verified: December 2013

Keywords provided by Gaab Soo Kim, Samsung Medical Center:
liver transplantation
vecuronium

Additional relevant MeSH terms:
Desflurane
Vecuronium Bromide
Anesthetics, Inhalation
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Neuromuscular Nondepolarizing Agents
Neuromuscular Blocking Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Nicotinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action